St-Priest, 9 September 2015, 7:30 AM CET - Biom'Up today announced that the company has secured EUR 31,3 million in a Series C financing round from an investment syndicate consisting of Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, alongside its existing shareholders (InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l'Améliane) and the company's...
Financing will advance Sanifit's lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and throughphase II/III for calciphylaxis.Palma de Mallorca, Spain, September 8, 2015 - Laboratoris Sanifit S.L., a clinical-stagebiopharmaceutical company, today announces that it has raised ?36.6M ($41.3M) in a SeriesC financing round. The company is focused on the...
Lundbeck Foundation has granted DKK 10 million to a ground-breaking research project aimed at identifying new types of medicine for strokes.
Lund, Sweden, (PRNEWSWIRE) August 25, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that its platform bone void filler, CERAMENTT with antibiotics, will have a significant presence at the upcoming 34th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) taking...
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015.
Post-Hoc Analyses of Data Show Preliminary Evidence of Overall Disease Stabilization with Improvement in Several Disease Domains
CANTERBURY, UK, 20 JULY, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Mike Grey as Executive Chairman of its Board of Directors, effective immediately. Mr. Grey first joined the Company's board as an independent director in December 2014. 
Poul la Cour joins Lundbeckfond Invest
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily...
1 2 3 4 5 7


90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge